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Airi Sekine, Misaki Okamoto, Yuka Kanatani, Mitsue Sano, Katsumi Shibata and Tsutomu Fukuwatari*Abstract
The tryptophan metabolite, kynurenic acid (KYNA), is a preferential antagonist of the α7 nicotinic acetylcholine
receptor at endogenous brain concentrations. Recent studies have suggested that increase of brain KYNA levels is
involved in psychiatric disorders such as schizophrenia and depression. KYNA-producing enzymes have broad
substrate specificity for amino acids, and brain uptake of kynurenine (KYN), the immediate precursor of KYNA, is via
large neutral amino acid transporters (LAT). In the present study, to find out amino acids with the potential to
suppress KYNA production, we comprehensively investigated the effects of proteinogenic amino acids on KYNA
formation and KYN uptake in rat brain in vitro. Cortical slices of rat brain were incubated for 2 h in Krebs-Ringer buffer
containing a physiological concentration of KYN with individual amino acids. Ten out of 19 amino acids (specifically,
leucine, isoleucine, phenylalanine, methionine, tyrosine, alanine, cysteine, glutamine, glutamate, and aspartate)
significantly reduced KYNA formation at 1 mmol/L. These amino acids showed inhibitory effects in a dose-dependent
manner, and partially inhibited KYNA production at physiological concentrations. Leucine, isoleucine, methionine,
phenylalanine, and tyrosine, all LAT substrates, also reduced tissue KYN concentrations in a dose-dependent manner,
with their inhibitory rates for KYN uptake significantly correlated with KYNA formation. These results suggest that five
LAT substrates inhibit KYNA formation via blockade of KYN transport, while the other amino acids act via blockade of
the KYNA synthesis reaction in brain. Amino acids can be a good tool to modulate brain function by manipulation
of KYNA formation in the brain. This approach may be useful in the treatment and prevention of neurological and
psychiatric diseases associated with increased KYNA levels.
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Neuropsychiatric disordersBackground
Tryptophan was mainly metabolized through the kynur-
enine (KYN) pathway in the mammalian brain. Kynurenic
acid (KYNA), a product of this pathway, is a negative allo-
steric modulator of the α7 nicotinic acetylcholine receptor
at endogenous concentration, and a competitive antagon-
ist of glycine co-agonist sites of the N-methyl-D-aspartic
acid receptor (Kessler et al. 1989; Hilmas et al. 2001;
Schwarcz and Pellicciari 2002). In particular, nanomolar
increases in KYNA reduces dopaminergic and glutamater-
gic neurotransmission (Carpenedo et al. 2001; Rassoulpour
et al. 2005), and contributes to cognitive dysfunction* Correspondence: fukkie@shc.usp.ac.jp
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in any medium, provided the original work is p(Erhardt et al. 2004; Chess and Bucci 2006; Chess et al.
2007; Chess et al. 2009). While decreases in endogenous
KYNA augment dopaminergic, acetylcholinergic and
glutamatergic neurotransmission (Amori et al. 2009a;
Zmarowski et al. 2009; Konradsson-Geuken et al. 2010),
and lead to enhanced cognitive abilities (Potter et al. 2010;
Kozak et al. 2014). In humans, patients with schizophrenia
show higher KYNA levels in the prefrontal cortex and
cerebrospinal fluid (Erhardt et al. 2001; Schwarcz et al.
2001; Linderholm et al. 2010). Based on these findings, it
has been suggested that KYNA is involved in the patho-
physiology of psychiatric disorders including schizophre-
nia (Erhardt et al. 2007; Erhardt et al. 2009), and thus,
suppression of KYNA production may contribute to pre-
vention or improvement in these disorders.n open access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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of KYNA, from blood stream, and KYN is metabolized
to KYNA. Two factors regulate KYNA production in the
brain: kynurenine amino transferase (KAT) activity and
availability of KYN (Turski et al. 1989). Four KATs have
been identified in the mammalian brain, these KATs
have broad substrate specificity for amino acids, and sev-
eral amino acids competitively inhibit KATs for KYNA
production (Okuno et al. 1991; Guidetti al. 2007; Han
et al. 2010). Hence, amino acids may suppress KYNA
production via KAT inhibition in the brain. Astrocytes
uptake peripheral KYN from blood stream via large neu-
tral amino acid transporters (LATs). LATs are known to
transport both branched chain amino acids (e.g., valine,
leucine and isoleucine) and aromatic amino acids (e.g.,
tyrosine, phenylalanine, and tryptophan). Several find-
ings show that LATs transport amino acids with higher
affinity than KYN in tumor cell lines (Fukui et al. 1991;
Speciale et al. 1989; Asai et al. 2008; Yanagida et al. 2001),
and changes in physiological concentrations of these amino
acids may affect KYN transport into the brain.
In the present study, we comprehensively investigated
the effects of amino acids on suppression of KYNA pro-
duction via inhibition of KYN uptake and KYNA synthe-
sis in the brain. We used brain slices to determine the
inhibitory effects on KYNA synthesis, KYN uptake and
KYNA synthesis at physiological KYN concentrations.
Our findings demonstrate that amino acids are a good tool
for modulating brain function by manipulating KYNA for-
mation in the brain.Methods
Animals
Male Wistar rats (7–10 weeks old) were obtained from
CLEA Japan (Tokyo, Japan). Rats were allowed free access
to food and water. The animal room was maintained at a
temperature of 22°C with 60% humidity and a 12-h light/
12-h dark cycle (light onset at 6:00 a.m.). Care and treat-
ment of experimental animals conformed to the University
of Shiga Prefecture guidelines for ethical treatment of
laboratory animals (reference number: 24-9).Chemicals
L-Kynurenine sulfate salt, KYNA, and L-tyrosine disodium
salt hydrate were purchased from Sigma Chemical
Co. (St. Louis, MO, USA). L-Alanine, L-arginine, L-
asparagine, L-aspartate, L-cysteine hydrochloride mono-
hydrate, L-glutamine, L-glutamate, L-glycine, L-histidine,
L-isoleucine, L-leucine hydrochloride, L-lysine, L-methio-
nine, L-phenylalanine, L-proline, L-serine, L-threonine,
and L-valine were purchased from Wako Pure Chemical
Industries (Osaka, Japan). Rodent diet (MF) was obtained
from Oriental Yeast Co., Ltd (Tokyo, Japan). All otherchemicals were of the highest commercially available
purity.
Tissue preparation
De novo formation of KYNA was established using tissue
slices, as described previously Turski et al. (1989). Ani-
mals were killed by decapitation and brains removed
rapidly. The cortex was rapidly dissected out and kept in
a minimal volume of ice-cold Krebs-Ringer buffer (KRB:
118.5 mmol/L NaCl, 4.8 mmol/L KCl, 1.8 mmol/L CaCl2,
1.2 mmol/L MgSO4, 16.2 mmol/L NaH2PO4, 5.0 mmol/L
glucose, pH 7.4). Tissue slices (1 × 1 mm) were made
using a McIlwain tissue slicer (Muromachi Kikai Co., Ltd,
Tokyo, Japan), and placed in ice-cold KRB until the start
of experiments (<1 h).
In vitro screening of amino acids regulating de novo
KYNA formation
Routinely, seven tissue slices were placed in each culture
well (seven slices per well, ~1 mg of total protein) con-
taining a final volume of 1 mL ice-cold KPB and final
concentration of 1 mmol/L each amino acid for screening,
or 3–3000 mmol/L each amino acid for dose–response
assays. After 10 min pre-incubation at 37°C in an oxy-
genated shaking water bath, a final physiological con-
centration of 2 μmol/L KYN was added to each well.
After 2 h incubation at 37°C, plates were placed on ice.
Because assessment of the time course of KYNA con-
centration in KRB showed linear increases up to 4 h of
incubation (Turski et al. 1989), biochemical viability of
brain tissue was maintained during the study period.
The medium was rapidly separated from the tissue and
acidified with 100 μL of 1 mol/L HCl for subsequent
KYNA measurements. We described KYNA concentra-
tion in the incubation medium as KYNA production,
because more than 90% of newly synthesized KYNA
readily liberate from tissue slices into the medium
(Turski et al. 1989). The tissue slices were rapidly washed
three times with 500 μL of KRB and sonicated using an
ultrasonic cell breaker (Powersonic model 50; Yamato
Kagaku, Tokyo, Japan) in 250 μL distilled water. The 200-
μL aliquot of tissue slice suspension was acidified using
50 μL of 6% perchloric acid. After centrifugation (10 min,
12,000 × g, 4°C), the supernatant aliquot was used for
KYN determination of component compound. A 50-μL
aliquot of tissue slice suspension was used for protein
determination using the Bradford assay (Bradford 1976).
KYNA and KYN determination
KYNA concentration in the samples was determined by
high-performance liquid chromatography with fluores-
cence detection (RF-20Axis; Shimadzu, Kyoto, Japan)
at 344 nm excitation and 398 nm emission wavelengths
(Shibata 1988). KYN concentration was determined by
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detection (SPD-10AV; Shimadzu) at a 365 nm wavelength
(Holmes 1988).
Statistical analysis
All data were expressed as mean ± SE. One-way analysis
of variance with Dunnett’s Multiple Comparison Test
was used for more than three-group comparisons. Sig-
moid curves were generated by nonlinear regression
analysis. We calculated the half-maximal inhibitory con-
centration (IC50 values in μmol/L) of each amino acid
for KYNA production and KYN uptake using the equa-
tion “log (inhibitor) vs. response” by GraphPad Prism 5.0
(GraphPad Software, San Diego, CA, USA).
Correlation between inhibitory rates for KYNA pro-
duction and tissue KYN concentration by amino acids
were represented by linear regression of data. Inhibitory
rates for KYNA production and tissue KYN concentra-
tion at each additional amino acid concentrations were
described by the percentage of control values. Correlation
between KYNA production and KYN uptake at various
KYN concentrations in the KRB were also represented by
linear regression of data. KYNA production and KYN up-
take were described by the percentage of 2 μmol/L KYN
control values. Pearson correlation coefficient was calcu-


































Figure 1 Effect of 1 mmol/L amino acids on (a) KYNA production and
cortex. Experiments were performed as described in the text using 2 μmo
tissue slice suspension, respectively. Values are expressed as mean ± SE (n =
variance with Dunnett’s multiple comparisons test.A p-value < 0.05 was considered significant. GraphPad
Prism 5.0 (GraphPad Software, San Diego, CA, USA) was
used for all analyses.
Results
Screening amino acids for suppression of KYNA
production
To determine which amino acids suppress KYNA produc-
tion in vitro, we comprehensively assessed 19 proteino-
genic amino acids at 1 mmol/L using tissue slices from
the rat cerebral cortex. Because commercially available
tryptophan contains tryptophan metabolites (including
KYN and KYNA), we excluded tryptophan from our initial
list of 20 proteinogenic amino acids. The amount of
KYNA in the extracellular medium was reduced by 40–
60% by eight amino acids (leucine, isoleucine, methionine,
alanine, tyrosine, glutamine, glutamate, and aspartate),
and to approximately 25% by phenylalanine and cysteine
(Figure 1a). Leucine, isoleucine, methionine, phenyl-
alanine, and tyrosine also reduced tissue KYN concen-
trations to < 50% (Figure 1b). No significant difference
was observed for tissue KYN concentrations using alanine,
cysteine, glutamine, glutamate, and aspartate, which all
reduced KYNA production. Although valine reduced
tissue KYN concentrations to 50%, it did not suppress






























(b) tissue KYN concentration in tissue slices from the cerebral
l/L KYN. KYNA and KYN were measured in incubation medium and









































































































































































































































































































































Figure 2 (See legend on next page.)
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Figure 2 Dose-dependent inhibition of KYNA production in tissue slices from the cerebral cortex by (a) leucine (Leu), (b) isoleucine
(Ile), (c) phenylalanine (Phe), (d) tyrosine (Tyr), (e) methionine (Met), (f) cysteine (Cys), (g) aspartate (Asp), (h) glutamine (Gln), (i) alanine
(Ala), and (j) glutamate (Glu). Experiments were performed as described in the text using 2 μmol/L KYN. KYNA was measured in incubation
medium. Values are expressed as mean ± SE (n = 4–6). Sigmoid curves were generated by nonlinear regression analysis using Graph Pad Prism 5.0.
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and KYN uptake
Since 10 of the 19 proteinogenic amino acids signi-
ficantly reduced KYNA formation at 1 mmol/L, these
amino acids were chosen for further investigation. To
determine the precise capabilities of 10 amino acids
to suppress KYNA production, each amino acid was
added to KRB at concentrations varying from 3 μmol/L
to 3 mmol/L. All 10 amino acids reduced KYNA pro-
duction in a dose-responsive manner (Figure 2). Five
amino acids (leucine, isoleucine, phenylalanine, methio-
nine, and tyrosine) also reduced tissue KYN concentra-
tion in a dose-responsive manner (Figure 3). The other
amino acids (alanine, aspartate, cysteine, glutamine, and
glutamate) did not affect tissue KYN concentrations. In
addition, we determined IC50 values for KYNA pro-
duction and KYN uptake. The rank order of IC50 values for
KYNA production was phenylalanine < leucine < isoleucine
< glutamate < cysteine < alanine < methionine < aspartate
< glutamine < tyrosine (Table 1), and for KYN uptake
was phenylalanine > leucine > isoleucine >methionine > tyro-
sine (Table 1).
Amino acid contribution of KYN uptake inhibition to
KYNA production
To determine how inhibition of KYN uptake affects
KYNA production, we selected five amino acids which
reduced not only KYNA production but tissue KYN
concentration, and examined the relationship between
KYN uptake and KYNA production. Inhibitory rates of
KYN uptake were significantly correlated with KYNA pro-
duction by leucine (y = 1.04x – 5.6, r = 0.988; p < 0.0001),
isoleucine (y = 0.904x + 5.9, r = 0.987; p < 0.0001), phenyl-
alanine (y = 1.03x – 7.0, r = 0.945; p < 0.001), methio-
nine (y = 1.25x – 28.0, r = 0.889; p < 0.01), and tyrosine
(y = 0.921x – 7.7, r = 0.967; p < 0.0001) (Figure 4). Com-
bining data from the respective amino acids showed
significantly high correlation (y = 0.981x – 1.1, r = 0.946;
p < 0.0001) (Figure 4f ). To determine the direct rela-
tionship between tissue KYN concentration and KYNA
production, cortical slices were incubated in KRB con-
taining 0.4–2 μmol/L KYN. KYNA production and tis-
sue KYN level were described the percentage of 2 μmol/L
KYN control. With increasing KYN concentrations, KYNA
production and tissue KYN concentration linearly in-
creased in a dose-dependent manner (Figure 5a and b).
Moreover, KYNA production was strongly correlated withtissue KYN concentration (y = 0.978x – 4.5, r = 0.985;
p < 0.01) (Figure 5c). This relationship (including slope of
the regression line) was the same for inhibitory effects of
all five amino acids. These results suggest that inhibition
of KYN uptake, but not KAT activity, contributes to inhi-
bitory effects of these five large neutral amino acids on
KYNA production.
Discussion
Previous reports have shown that amino acids have the
potential to suppress KYNA production via inhibition of
KYN uptake and KYNA synthesis in the brain, therefore
we comprehensively investigated the effects of proteino-
genic amino acids on regulating KYNA production in
rat brain in vitro. We show that 10 of 19 amino acids
(specifically, leucine, isoleucine, phenylalanine, methio-
nine, tyrosine, alanine, cysteine, glutamine, glutamate,
and aspartate) significantly reduce KYNA production at
the tissue level. Five (leucine, isoleucine, phenylalanine,
methionine, and tyrosine) of these 10 amino acids also
reduce tissue KYN concentration, with inhibition of KYNA
production reflecting these reductions in KYN uptake. Our
results suggest that these five amino acids suppress KYNA
production via blockade of KYN transport, while the
other five amino acids (alanine, cysteine, glutamine,
glutamate, and aspartate) act via blockade of KYNA syn-
thesis in the brain.
KYN is transported into the brain via LATs, which are
Na+-independent neutral amino acids transporters. There
are two LATs, LAT 1 and LAT 2, with the affinity of LAT
1 to large neutral amino acids higher than that of LAT 2.
LAT 1 exhibits high-affinity transport of large neutral
amino acids, including branched chain and aromatic
amino acids, while LAT 2 has broader substrate specific-
ities (Kanai et al. 1998; Segawa et al. 1999). The Km value
of LATs for KYN is ~160 μmol/L, 80 times higher than
plasma KYN concentrations (Fukui et al. 1991; Speciale
et al. 1989). In the present study, the amino acids that
inhibited KYN uptake are consistent with substrate amino
acids of LAT 1 rather than LAT 2, suggesting a critical
role of LAT 1 in KYN uptake in the brain. Km values of
LAT 1 for leucine, isoleucine, methionine, phenylalanine,
and tyrosine are 15–30 μmol/L, around physiological con-
centrations (Asai et al. 2008), indicating higher affinity
than for KYN (Yanagida et al. 2001). The other amino
acids (glutamine and aspartate) have low affinity for
































































































































































































































































































































Figure 3 (See legend on next page.)
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Figure 3 Dose-dependent inhibition of tissue KYN concentration in tissue slices from cerebral cortex by (a) leucine (Leu), (b) isoleucine
(Ile), (c) phenylalanine (Phe), (d) tyrosine (Tyr), (e) methionine (Met), (f) cysteine (Cys), (g) aspartate (Asp), (h) glutamine (Gln), (i) alanine (Ala),
and (j) glutamate (Glu). Experiments were performed as described in the text using 2 μmol/L KYN. KYN was measured in tissue slice suspension.
Values are expressed as mean ± SE (n = 4–6). Sigmoid curves were generated by nonlinear regression analysis using Graph Pad Prism 5.0.
Sekine et al. SpringerPlus  (2015) 4:48 Page 7 of 10of LAT nor affect tissue KYN concentration. Histidine
is also known to be a high affinity substrate for LAT 1
(Km = 12.7 μmol/L), but did not reduce tissue KYN con-
centration in the present study. KYN is transported
through either Na-independent or Na-dependent matter
in tissue slice culture (Turski et al. Turski et al. 1989). In
this study, only Na-independent LATs substrates such
as leucine, but not Na-dependent LATs substrates such as
glutamine, reduced KYN uptake. Na-independent trans-
port rather than Na-dependent transport may contribute
KYN uptake, and regulating of Na-independent LATs may
be effective in modulating KYN uptake.
The mammalian brain expresses four KATs, KAT I
(glutamine transaminase K, GTK; EC 2.6.1.64), KAT II
(2-aminoadipate aminotransferase, ADA; EC 2.6.1.7),
KAT III (cysteine conjugate β-lyase 2, CCBL2; EC4.4.1.13)
and KAT IV (mitochondrial aspartate aminotransferase,
ASAT; EC 2.6.1.1). A previous study determined the rela-
tive contributions of KAT I, II, and IV to total KAT activ-
ity, and found that rat and human brain contain the
highest proportion of KAT II (~60%) (with ~10 and 30%
of KAT I and IV, respectively) suggesting a critical role
for KAT II in KYNA synthesis in rat and human brain
(Guidetti et al. 2007). KAT III contribution to brain
KYNA synthesis remains to be determined. In the present
study, glutamate, aspartate, cysteine, glutamine, and ala-
nine suppressed KYNA production but not KYN uptake,
suggesting that these amino acids inhibit the KYNA syn-
thesis reaction. Glutamate and aspartate strongly inhibitTable 1 IC50 values for KYNA production and KYN uptake
using 10 selected amino acids













Glutamine 647 —KAT II (IC50: 2.1 and 1.2 mmol/L, respectively) and IV
(IC50: 0.9 and 0.3 mmol/L, respectively), while glutamine
and cysteine show inhibitory effects on KAT I and III
activities (Guidetti et al. 2007; Han et al. 2009; Han et al.
2010). Furthermore, cysteine sulfinate, the deoxygenated
product of cysteine, acts as a KAT II inhibitor and
inhibits rat brain KYNA production at physiological
concentrations in vitro (Kocki et al. 2003). Our results
cannot determine if cysteine, cysteine sulfinate, or both
inhibit the KYNA synthesis reaction. LAT 1 substrates
(leucine, methionine, and phenylalanine) also inhibit
KAT III activity (Han et al. 2009). In the present study,
inhibition of KYNA production reflects reduced KYN
uptake, and we did not observe additional effects of
KAT inhibition.
We precisely investigated the effect of 10 amino
acids on KYNA production and KYN uptake at 3 μmol/
L–3 mmol/L. The physiological concentrations of leucine,
isoleucine, phenylalanine, methionine, tyrosine, alanine,
aspartate, cysteine, glutamine, and glutamate are approxi-
mately 150, 90, 60, 50, 70, 400, 10, 10, 700, and 80 μmol/L
in rat plasma, respectively (Asai et al. 2008). Interestingly,
all 10 amino acids partially inhibited KYNA production at
physiological concentrations, with IC50 values of most
amino acids for KYNA production or KYN uptake around
physiological levels. Although the LATs mediating KYN
uptake in blood–brain barrier is not completely identical
to the tissue slices in the present study, it is expected that
changes in physiological concentrations of these amino
acids may affect brain KYNA levels in vivo. In particular,
increases in plasma levels of these amino acids may lower
brain KYNA levels.
Enhancement of brain KYNA production can be
caused by pharmacological manipulation of KYN such
as through systemic KYN administration or kynurenine
3-hydroxylase inhibitor in vivo (Swartz et al. 1990; Röver
et al. 1997; Lombardi et al. 1994; Rassoulpour et al.
2005). Pharmacological manipulation of KAT suppresses
KYNA production in the brain in vivo (Amori et al.
2009a; Amori et al. 2009b; Dounay et al. 2012; Kozak
et al. 2014). In addition, recent studies have shown that
diet also affects brain KYNA concentrations. High trypto-
phan diets increase brain KYNA levels owing to increased
peripheral KYN in a dose-dependent manner, and reduce
dopamine release via enhancement of KYNA production
in the rat striatum (Okuno et al. 2011). Long-term expos-
ure to a high-fat and low-protein/carbohydrate ketogenic
Leu
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y = 0.981x – 1.13
y = 1.25x – 28.0
y = 1.04x – 5.55 y = 0.904x + 5.88
p < 0.0001
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Large neutral amino acids



























Pearson r = 0.945
y = 1.03x – 7.04
Pearson r = 0.967
y = 0.921x + 7.65
Figure 4 Correlation between inhibitory rates for KYNA production and tissue KYN concentration by (a) leucine (Leu), (b) isoleucine
(Ile), (c) phenylalanine (Phe), (d) tyrosine (Tyr), (e) methionine (Met), and (f) all five large neutral amino acids. Values are expressed as
mean ± SE (n = 4–6). Lines represent linear regression of data.
Sekine et al. SpringerPlus  (2015) 4:48 Page 8 of 10diet shows a several-fold increase in KYNA concentra-
tions in the rat brain (Żarnowski et al. 2012). Because
amino acids are nutritional factors and often used as
supplements, their side effects, safety doses, and inter-
actions have been well investigated. Thus, long-term ad-
ministration of amino acids from a diet may be a good
method to manipulate KYNA formation in the brain.
Several studies suggest that dietary large neutral amino
acids modulated neurotransmitter release via LAT. For
example, ingestion of α-lactalbumin-containing diet, a
tryptophan-rich protein, increase brain Tryptophan con-
tent and serotonin synthesis and release (Choi et al. 2009;Orosco et al. 2004). Branched-chain amino acids inges-
tion causes the decline in tyrosine uptake and dopamine
synthesis in brain (Fernstrom 2013). We suggest that
large neutral amino acids may expand glutamate or
acetylcholine release by suppressing KYNA production.
In this study, we also show that non-large neutral amino
acids, alanine, cysteine, glutamine and glutamate reduce
KYNA production. Our findings may highlight the im-
portance of dietary amino-acid compositions in brain
chemistry and function. It will be interesting to determine
the amino acid composition of habitual diets in patients
with psychiatric disorders.










































































Pearson r = 0.988
y = 0.978x – 4.5
p < 0.01
Figure 5 Effect of KYN on (a) KYNA production and (b) KYN
uptake in tissue slices from the cerebral cortex, and (c)
correlation between KYNA production and KYN uptake. Values
are expressed as mean ± SE (n = 3). Lines represent linear regression
of data.
Sekine et al. SpringerPlus  (2015) 4:48 Page 9 of 10Conclusions
We have investigated the effect of proteinogenic amino
acids on KYNA production in rat brain in vitro. Our
results show that amino acids can partially regulate KYNA
production at physiological concentrations, and that some
modulate KYN uptake, while others the KYNA synthesis
reaction. Although animal studies are required to show
the effect of these amino acids on KYNA production
in vivo, amino acids have the potential to regulate
KYNA formation and release of neurotransmitters such as
dopamine, acetylcholine, and glutamate. Recent studies
suggest that KYNA is involved in the pathophysiology
of psychiatric disorders, including schizophrenia (Erhardt
et al. 2007; Erhardt 2009). In addition, recent studies show
that manipulations of peripheral KYN modulate depres-
sion-like behavior induced by stress (Agudelo 2014). Be-
cause diet affects brain KYN and KYNA concentration,
long-term administration of amino acids through a diet
may also affect KYNA production via regulating brain
KYN uptake or KYNA synthesis. This approach may be
useful in the treatment and prevention of neurological
and psychiatric diseases associated with increased KYNA
levels.
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